Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Precision Oncology: 2024 in Review
This article discusses the specific advances made in precision oncology in 2024. We
comment on the evolving nature of predictive molecular events used to select patients who …
comment on the evolving nature of predictive molecular events used to select patients who …
Map** kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Mutations in the kinase and juxtamembrane domains of the MET Receptor Tyrosine Kinase
are responsible for oncogenesis in various cancers and can drive resistance to MET …
are responsible for oncogenesis in various cancers and can drive resistance to MET …
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology
Objectives MET exon 14 skip** alterations (METex14+) represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) with distinct biological and genomic …
subgroup of non-small cell lung cancer (NSCLC) with distinct biological and genomic …
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
K Verkerk, TJWT van der Wel, LJ Zeverijn… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: To provide patients with MET-mutated advanced non–small cell lung cancer (MET
mut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in …
mut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in …
[HTML][HTML] MET Exon 14 Skip** and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients
Targeted therapy indications for actionable variants in non-small-cell lung cancer (NSCLC)
have primarily been studied in Caucasian populations, with limited data on Latin American …
have primarily been studied in Caucasian populations, with limited data on Latin American …
Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding
Small molecule kinase inhibitors are critical in the modern treatment of cancers, evidenced
by the existence of over 80 FDA-approved small-molecule kinase inhibitors. Unfortunately …
by the existence of over 80 FDA-approved small-molecule kinase inhibitors. Unfortunately …
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung
Adenocarcinoma | JCO Precision Oncology Skip to main content ASCO Publications …
Adenocarcinoma | JCO Precision Oncology Skip to main content ASCO Publications …
[PDF][PDF] MET Exon 14 Skip** and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients.
S Rivas, RV Sepulveda, I Tapia, C Estay, V Soto… - 2024 - preprints.org
Targeted therapy indications for actionable variants in non-small cell lung cancer (NSCLC)
have primarily been studied in Caucasian populations, with limited data on Latin American …
have primarily been studied in Caucasian populations, with limited data on Latin American …
Resistance to Allosteric Inhibitors
I Outhwaite, I Kwan, NP Shah, I Bahar… - Available at SSRN … - papers.ssrn.com
Allosteric inhibitors have emerged as powerful therapeutic agents capable of overcoming
resistance mutations that impair the efficacy of orthosteric inhibitors. However, resistance to …
resistance mutations that impair the efficacy of orthosteric inhibitors. However, resistance to …